Cargando…

Preventive treatment response associated with migraine aura subtypes in a Thai population

INTRODUCTION: Some studies indicate a different response to treatment between migraine patients with and without aura. OBJECTIVES: To determine whether aura, or simple or complex aura subtypes, are clinical markers predicting response to preventive treatment. METHODS: Conducted a retrospective cohor...

Descripción completa

Detalles Bibliográficos
Autores principales: Asawavichienjinda, Thanin, Storer, Robin James
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9868607/
https://www.ncbi.nlm.nih.gov/pubmed/36699963
http://dx.doi.org/10.3389/fnhum.2022.1065859
_version_ 1784876577059766272
author Asawavichienjinda, Thanin
Storer, Robin James
author_facet Asawavichienjinda, Thanin
Storer, Robin James
author_sort Asawavichienjinda, Thanin
collection PubMed
description INTRODUCTION: Some studies indicate a different response to treatment between migraine patients with and without aura. OBJECTIVES: To determine whether aura, or simple or complex aura subtypes, are clinical markers predicting response to preventive treatment. METHODS: Conducted a retrospective cohort study at a headache clinic in a tertiary referral hospital. We included data from patients registered from 1 November 2014, to 30 June 2022, having migraine with or without aura, or with simple or complex aura, and who had received migraine preventive treatments with at least 3 months follow-up. The primary outcome was a response to preventive treatment defined as at least a 50% reduction from a baseline of monthly migraine or headache days (MMDs/MHDs). Secondary outcomes were improvement in quality of life and disability scores. RESULTS: For migraine patients with (45) and without (123) aura who took a migraine preventive with at least 3 months follow-up; except for median age, which was older for patients without aura, baseline sex, comorbidity, and migraine data were without significant difference including median history of migraine, chronic migraine subtype, chronic migraine with medication-overuse headache, median or mean MMDs/MHDs, number of preventive medications used, or migraine preventive medication inhibiting spreading depolarizations. Treatment outcomes at 3 and 6 months follow-up were not significantly different between migraine patients with and without aura, or with simple and complex aura, but tended to be greater in those with aura and those with complex aura. After adjustment for baseline comorbidity, migraine subtypes, aura subtypes, the number of preventives used, history of migraine, and MMDs/MHDs, we found no significant differences in 30% and 50% reduction from baseline of MMDs/MHDs in 3 or 6 months or most recent follow-up. CONCLUSIONS: Preventive treatment response tended to be associated with migraine aura subtypes. We found preventive treatment response tended to have more favorable outcomes in those with aura, especially those with complex aura.
format Online
Article
Text
id pubmed-9868607
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-98686072023-01-24 Preventive treatment response associated with migraine aura subtypes in a Thai population Asawavichienjinda, Thanin Storer, Robin James Front Hum Neurosci Neuroscience INTRODUCTION: Some studies indicate a different response to treatment between migraine patients with and without aura. OBJECTIVES: To determine whether aura, or simple or complex aura subtypes, are clinical markers predicting response to preventive treatment. METHODS: Conducted a retrospective cohort study at a headache clinic in a tertiary referral hospital. We included data from patients registered from 1 November 2014, to 30 June 2022, having migraine with or without aura, or with simple or complex aura, and who had received migraine preventive treatments with at least 3 months follow-up. The primary outcome was a response to preventive treatment defined as at least a 50% reduction from a baseline of monthly migraine or headache days (MMDs/MHDs). Secondary outcomes were improvement in quality of life and disability scores. RESULTS: For migraine patients with (45) and without (123) aura who took a migraine preventive with at least 3 months follow-up; except for median age, which was older for patients without aura, baseline sex, comorbidity, and migraine data were without significant difference including median history of migraine, chronic migraine subtype, chronic migraine with medication-overuse headache, median or mean MMDs/MHDs, number of preventive medications used, or migraine preventive medication inhibiting spreading depolarizations. Treatment outcomes at 3 and 6 months follow-up were not significantly different between migraine patients with and without aura, or with simple and complex aura, but tended to be greater in those with aura and those with complex aura. After adjustment for baseline comorbidity, migraine subtypes, aura subtypes, the number of preventives used, history of migraine, and MMDs/MHDs, we found no significant differences in 30% and 50% reduction from baseline of MMDs/MHDs in 3 or 6 months or most recent follow-up. CONCLUSIONS: Preventive treatment response tended to be associated with migraine aura subtypes. We found preventive treatment response tended to have more favorable outcomes in those with aura, especially those with complex aura. Frontiers Media S.A. 2023-01-09 /pmc/articles/PMC9868607/ /pubmed/36699963 http://dx.doi.org/10.3389/fnhum.2022.1065859 Text en Copyright © 2023 Asawavichienjinda and Storer. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neuroscience
Asawavichienjinda, Thanin
Storer, Robin James
Preventive treatment response associated with migraine aura subtypes in a Thai population
title Preventive treatment response associated with migraine aura subtypes in a Thai population
title_full Preventive treatment response associated with migraine aura subtypes in a Thai population
title_fullStr Preventive treatment response associated with migraine aura subtypes in a Thai population
title_full_unstemmed Preventive treatment response associated with migraine aura subtypes in a Thai population
title_short Preventive treatment response associated with migraine aura subtypes in a Thai population
title_sort preventive treatment response associated with migraine aura subtypes in a thai population
topic Neuroscience
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9868607/
https://www.ncbi.nlm.nih.gov/pubmed/36699963
http://dx.doi.org/10.3389/fnhum.2022.1065859
work_keys_str_mv AT asawavichienjindathanin preventivetreatmentresponseassociatedwithmigraineaurasubtypesinathaipopulation
AT storerrobinjames preventivetreatmentresponseassociatedwithmigraineaurasubtypesinathaipopulation